NCT06970951View on ClinicalTrials.gov

Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 18, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

April 30, 2027

Conditions
Systemic Lupus ErythematosusRheumatoid ArthritisDry SyndromeIdiopathic Inflammatory MyopathiesSystemic Sclerosis
Interventions
BIOLOGICAL

UTAA91 injection

Infusion of UTAA91 injection in subjects screened after signing informed consent.

Trial Locations (1)

215000

The First Affiliated Hospital of Soochow University, Suzhou

Sponsors
All Listed Sponsors
lead

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

INDUSTRY